Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease - PubMed (original) (raw)
. 2000 Jul:123 ( Pt 7):1365-79.
doi: 10.1093/brain/123.7.1365.
Affiliations
- PMID: 10869049
- DOI: 10.1093/brain/123.7.1365
Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease
C S Lee et al. Brain. 2000 Jul.
Abstract
We investigated the role of dopamine neurons in the manifestation of levodopa-induced dyskinesia in a rat model of Parkinson's disease. Daily treatment with a subthreshold dose of levodopa gradually induced abnormal involuntary movements (AIM) in 6-hydroxydopamine-lesioned rats, which included stereotypy and contraversive rotation. After 4 weeks of levodopa treatment, rats with mild and severe AIM were assigned to two treatment subgroups. The graft subgroup received embryonic ventral mesencephalic tissue into the striatum, whilst the sham-graft subgroup received vehicle only. Rats continued to receive levodopa treatment for 3 months post-graft. Brain sections at the level of the basal ganglia were processed for autoradiography using a ligand for dopamine transporter, and in situ hybridization histochemistry for mRNAs encoding postsynaptic markers. Levodopa-induced AIM significantly improved in grafted rats. The severity of AIM correlated inversely with the density of dopamine nerve terminals in the striatum (P < 0. 001), with almost no AIM when the density of dopamine nerve terminals was >10-20% of normal. Embryonic dopamine neuronal grafts normalized not only mRNA expression for preproenkephalin (PPE) in the indirect pathway, but also mRNA expression for prodynorphin (PDyn) in the direct pathway, which was upregulated by levodopa treatment. AIM scores correlated linearly with expression of PPE mRNA in the indirect pathway (P < 0.001) and also with PDyn mRNA in the direct pathway (P < 0.001). We conclude that embryonic dopamine neuronal grafts may improve levodopa-induced dyskinesia by restoring altered activities of postsynaptic neurons, resulting not only from dopamine denervation, but also from levodopa therapy, provided that the density of striatal dopaminergic nerve terminals is restored above a 'threshold' level.
Similar articles
- Implanted reuptake-deficient or wild-type dopaminergic neurons improve ON L-dopa dyskinesias without OFF-dyskinesias in a rat model of Parkinson's disease.
Vinuela A, Hallett PJ, Reske-Nielsen C, Patterson M, Sotnikova TD, Caron MG, Gainetdinov RR, Isacson O. Vinuela A, et al. Brain. 2008 Dec;131(Pt 12):3361-79. doi: 10.1093/brain/awn192. Epub 2008 Nov 6. Brain. 2008. PMID: 18988638 Free PMC article. - New insights into the mechanism of drug-induced dyskinesia.
Loonen AJ, Ivanova SA. Loonen AJ, et al. CNS Spectr. 2013 Feb;18(1):15-20. doi: 10.1017/s1092852912000752. CNS Spectr. 2013. PMID: 23593652 Review. - Can fetal neural transplants restore function in monkeys with lesion-induced behavioural deficits?
Ridley RM, Baker HF. Ridley RM, et al. Trends Neurosci. 1991 Aug;14(8):366-70. doi: 10.1016/0166-2236(91)90165-q. Trends Neurosci. 1991. PMID: 1721744 Review.
Cited by
- Counteraction by nitric oxide synthase inhibitor of neurochemical alterations of dopaminergic system in 6-OHDA-lesioned rats under L-DOPA treatment.
Del-Bel E, Padovan-Neto FE, Szawka RE, da-Silva CA, Raisman-Vozari R, Anselmo-Franci J, Romano-Dutra AC, Guimaraes FS. Del-Bel E, et al. Neurotox Res. 2014 Jan;25(1):33-44. doi: 10.1007/s12640-013-9406-3. Epub 2013 Jun 27. Neurotox Res. 2014. PMID: 23807548 - Chronic 3,4-dihydroxyphenylalanine treatment induces dyskinesia in aphakia mice, a novel genetic model of Parkinson's disease.
Ding Y, Restrepo J, Won L, Hwang DY, Kim KS, Kang UJ. Ding Y, et al. Neurobiol Dis. 2007 Jul;27(1):11-23. doi: 10.1016/j.nbd.2007.03.013. Epub 2007 Apr 10. Neurobiol Dis. 2007. PMID: 17499513 Free PMC article. - Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease.
Wernig M, Zhao JP, Pruszak J, Hedlund E, Fu D, Soldner F, Broccoli V, Constantine-Paton M, Isacson O, Jaenisch R. Wernig M, et al. Proc Natl Acad Sci U S A. 2008 Apr 15;105(15):5856-61. doi: 10.1073/pnas.0801677105. Epub 2008 Apr 7. Proc Natl Acad Sci U S A. 2008. PMID: 18391196 Free PMC article. - Stronger Dopamine D1 Receptor-Mediated Neurotransmission in Dyskinesia.
Farré D, Muñoz A, Moreno E, Reyes-Resina I, Canet-Pons J, Dopeso-Reyes IG, Rico AJ, Lluís C, Mallol J, Navarro G, Canela EI, Cortés A, Labandeira-García JL, Casadó V, Lanciego JL, Franco R. Farré D, et al. Mol Neurobiol. 2015 Dec;52(3):1408-1420. doi: 10.1007/s12035-014-8936-x. Epub 2014 Oct 26. Mol Neurobiol. 2015. PMID: 25344317 - Understanding and prevention of "therapy-" induced dyskinesias.
Aviles-Olmos I, Kefalopoulou Z, Foltynie T. Aviles-Olmos I, et al. Parkinsons Dis. 2012;2012:640815. doi: 10.1155/2012/640815. Epub 2012 May 23. Parkinsons Dis. 2012. PMID: 22685687 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources